Search 

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) is a subsidiary and the innovative R&D unit of Tasly Pharmaceutical Co. Ltd. The company develops, produce and promote biological therapeutical products across cardiavasular, metabolic and oncological area.

Tasly Pharmaceutical was founded in 1994 and listed in Shanghai Stock Exchange in 2002, which is a pioneer and leading player in China's pharmaceutical industry focusing on developing, manufacturing and commercializing traditional Chinese medicine, biological drugs and chemical drugs. Tasly Biopharmaceuticals Co., Ltd. is a subsidiary of Tasly Pharmaceutical and a leading innovative biopharmaceutical company in China with integrated commercialization platform spanning the entire biologics value chain.
Tasly Biopharma with its headquarter in Shanghai focuses on the development of biologic drugs in the therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. Our target therapeutic areas are among the largest and fastest growing therapeutic areas in China, where biologics are expected to become one of the key growth drivers.
Pro-UK is an innovative biologics drug manufactured and commercialized by Tasly Biopharma, which is indicated for STEMI thrombolysis with a better efficacy and safety profile than alteplas. In addition to Pro-UK, we have a rich biopharmaceutical products under development.
Tasly has collaborated with various overseas companies, including Transgene, Pharnext, EA, Eli Lilly, APbio, etc.. Some of the assets from collaboration have been successfully transferred to China, and clinical trials have been initiated.
Tasly is actively looking for partnerships on clinical-stage to marketed assets, through straight licensing, co-development, strategic investment, etc. in the abovementioned disease areas to bring the asset to China market.

A start up company

Founded in 2016 with over $800 million assets under management, Terra Magnum Capital Partners ("TMCP" or "the firm") is a China-focused private equity firm specialized in both direct investments and fund investments.

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

Pls check us at company website.

see company website

Tianda Pharmaceutical Limited (455.HK) is a Hong Kong listing company, concentrated in the R&D, manufacturing and distribution of biochemicals, biologics, biosimilars, CHC, dietary supplements and TCM.The company has two pharmaceutical factories, one TCM herbal slice plant, one GSP Company, one CSO company and a R&D center, and several operating
platforms separately located in Sydney, Hong Kong, Shenzhen, Zhuhai and Kunming.Shanghai Pharmaceutical Holding Co Limited, one of the top three largest pharmaceutical companies in China, has invested in Tianda Pharmaceuticals.
The mutual parties share their resources, therefore Tianda could explore and develop its business by utilizing the resources of Shanghai Pharmaceuticals.

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

Founded in 2007 with a management capital of 10 billion, fousing on healthcare and manufacturing investment. Portfolios includes ASYMCHEN, HOTGENBIO, SUNNOV and other more than 70 companies.